Completed OBSERVATIONAL NCT00297856

Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine

Open, Prospective Study of the Safety of GSK Biologicals' Boostrix® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) Administered to a Cohort of Adolescents in a US Health Maintenance Organization (HMO)

Sponsor: GlaxoSmithKline

Conditions Acellular Pertussis Diphtheria Tetanus

Interventions Boostrix® Td (Tetanus diphtheria) vaccine

Updated 7 times since 2017 Last updated: Jan 9, 2014 Started: Mar 31, 2006 Primary completion: Dec 31, 2006 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Acellular Pertussis and Diphtheria, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 7 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 2 earlier versions

Feb 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Oakland, United States